BSN Tracker

tramadol

Brand: Ultram, ConZip, Ultracet (with acetaminophen)

⚠ BBW ISMP High Alert Beers Criteria Prototype: morphine
Drug Class: opioid analgesic (atypical) / SNRI-like analgesic
Drug Family: opioid
Subclass: centrally acting analgesic
Organ Systems: cns

Mechanism of Action

Dual mechanism: weak mu-opioid receptor agonism via itself and its CYP2D6-derived active metabolite O-desmethyltramadol (M1), plus inhibition of serotonin and norepinephrine reuptake (SNRI-like). Considered a Schedule IV substance, reflecting lower addiction potential than Schedule II opioids, though dependence still occurs.

mu-opioid receptor (MOR, via O-desmethyltramadol)SERT (serotonin transporter)NET (norepinephrine transporter)

Indications

  • moderate to moderately severe pain
  • off-label: fibromyalgia
  • off-label: restless leg syndrome

Contraindications

  • concurrent MAOI use
  • seizure disorders
  • acute intoxication with alcohol or opioids
  • children <12 years

Adverse Effects

Common

  • nausea
  • constipation
  • dizziness
  • headache
  • somnolence
  • pruritus

Serious

  • seizures (dose-dependent; lower seizure threshold)
  • serotonin syndrome (particularly with SSRIs/SNRIs/MAOIs)
  • respiratory depression (less than full opioids)
  • dependence and withdrawal

Pharmacokinetics (ADME)

Absorption well absorbed orally; bioavailability ~75%; food has minimal effect
Distribution protein binding ~20%; Vd ~2.6 L/kg
Metabolism CYP2D6 converts tramadol to active M1 (O-desmethyltramadol); CYP3A4 produces inactive N-desmethyltramadol
Excretion primarily renal; dose adjustment required in CrCl <30 mL/min
Half-life 6-7 hours (parent); 7-9 hours (M1)
Onset 30-60 minutes
Peak 1-4 hours
Duration 4-6 hours
Protein Binding 20%
Vd 2.6 L/kg

Drug Interactions

Drug / Agent Mechanism Severity
MAOIs serotonin syndrome; potentially fatal contraindicated
SSRIs/SNRIs serotonin syndrome risk via additive serotonergic activity major
CYP2D6 inhibitors reduce M1 formation and analgesic efficacy moderate
benzodiazepines/CNS depressants additive respiratory depression major

Nursing Considerations

  1. Tramadol's dual mechanism makes it subject to serotonin syndrome with SSRIs, SNRIs, TCAs, and MAOIs — perform complete medication reconciliation before administration and assess for serotonin syndrome symptoms.
  2. Seizure risk is dose-dependent and highest in patients with seizure history, CNS disorders, or concurrent use of other drugs that lower the seizure threshold.
  3. Tramadol is often perceived as 'safe' because it is Schedule IV; educate staff that respiratory depression, dependence, and serotonin syndrome are still serious risks.
  4. Dose reduction required in renal impairment (CrCl <30 mL/min: max 200 mg/day; CrCl <10 mL/min: administer every 12 hours); creatinine clearance must be assessed in all patients.

Clinical Pearls

  • Tramadol's serotonin syndrome risk with SSRIs is one of the most clinically important drug interactions in outpatient prescribing; the combination is extremely common in patients with concurrent depression and pain, yet many prescribers are unaware of this interaction.
  • The Schedule IV classification reflects tramadol's lower abuse potential compared to Schedule II opioids, yet physical dependence is common and withdrawal can be complex — including both opioid-type symptoms and SNRI discontinuation-type symptoms simultaneously.

Safety Profile

Pregnancy avoid
Lactation avoid
Renal Adjustment Required
Hepatic Adjustment Required
TDM Not required

Concordance Terms

Cross-referenced clinical concepts — click any term to see all content where it appears.

Moderate To Moderately Severe Pain Off-label: Fibromyalgia Off-label: Restless Leg Syndrome Opioid Analgesic (atypical) / SNRI-like Analgesic
← Back to Medications